AU776061B2 - An oncolytic adenovirus - Google Patents
An oncolytic adenovirus Download PDFInfo
- Publication number
- AU776061B2 AU776061B2 AU16181/01A AU1618101A AU776061B2 AU 776061 B2 AU776061 B2 AU 776061B2 AU 16181/01 A AU16181/01 A AU 16181/01A AU 1618101 A AU1618101 A AU 1618101A AU 776061 B2 AU776061 B2 AU 776061B2
- Authority
- AU
- Australia
- Prior art keywords
- promoter
- viral vector
- viral
- cells
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/007—Vector systems having a special element relevant for transcription cell cycle specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16563899P | 1999-11-15 | 1999-11-15 | |
US60/165638 | 1999-11-15 | ||
PCT/US2000/031590 WO2001036650A2 (fr) | 1999-11-15 | 2000-11-14 | Adenovirus oncolytique |
Publications (2)
Publication Number | Publication Date |
---|---|
AU1618101A AU1618101A (en) | 2001-05-30 |
AU776061B2 true AU776061B2 (en) | 2004-08-26 |
Family
ID=22599791
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU16181/01A Ceased AU776061B2 (en) | 1999-11-15 | 2000-11-14 | An oncolytic adenovirus |
Country Status (13)
Country | Link |
---|---|
US (1) | US7001596B1 (fr) |
EP (1) | EP1230378B1 (fr) |
JP (1) | JP4334174B2 (fr) |
CN (1) | CN1382218A (fr) |
AT (1) | ATE364091T1 (fr) |
AU (1) | AU776061B2 (fr) |
CA (1) | CA2380537C (fr) |
CY (1) | CY1107725T1 (fr) |
DE (1) | DE60035124T2 (fr) |
DK (1) | DK1230378T3 (fr) |
ES (1) | ES2288488T3 (fr) |
PT (1) | PT1230378E (fr) |
WO (1) | WO2001036650A2 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7361354B1 (en) | 1999-11-25 | 2008-04-22 | Viralytics Limited | Methods for treating malignancies expressing ICAM-1 using coxsackie a group viruses |
US7485292B2 (en) | 2002-12-18 | 2009-02-03 | Viralytics Limited | Method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020037274A1 (en) * | 1998-10-26 | 2002-03-28 | Angelica Williams | Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants |
US7078030B2 (en) * | 1999-11-15 | 2006-07-18 | Onyx Pharmaceuticals, Inc | Oncolytic adenovirus |
US7396679B2 (en) * | 1999-11-15 | 2008-07-08 | Onyx Pharmaceuticals, Inc. | Oncolytic adenovirus |
US7109029B2 (en) | 2001-02-23 | 2006-09-19 | Cell Genesys, Inc. | Vector constructs |
US20060099178A1 (en) | 2002-05-27 | 2006-05-11 | Holm Per S | Novel use of adenoviruses and nucleic acids coding therefor |
WO2004042025A2 (fr) | 2002-11-01 | 2004-05-21 | Cell Genesys, Inc. | Vecteur d'adenovirus specifique des cellules comprenant un promoteur specifique de ebv |
US20040191761A1 (en) * | 2003-03-27 | 2004-09-30 | Routes John M. | Modified adenoviral E1A constructs and methods of use thereof |
US20050095705A1 (en) * | 2003-04-15 | 2005-05-05 | Michael Kadan | Method for production of oncolytic adenoviruses |
US7485291B2 (en) * | 2003-06-03 | 2009-02-03 | Cell Genesys, Inc. | Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof |
US20050136035A1 (en) * | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
WO2005017149A1 (fr) * | 2003-06-03 | 2005-02-24 | Cell Genesys, Inc. | Compositions et methodes pour une expression amelioree de polypeptides recombinants a partir d'un vecteur unique, faisant appel a un site de clivage peptidique |
AU2004263274B2 (en) | 2003-07-21 | 2009-11-05 | Transgene S.A. | Novel multifunctional cytokines |
WO2005030261A1 (fr) * | 2003-08-28 | 2005-04-07 | Cell Genesys, Inc. | Vecteurs adenoviraux oncolytiques codants pour gm-csf |
CN1528887A (zh) * | 2003-10-15 | 2004-09-15 | 中国科学院上海生命科学研究院 | 肿瘤靶向双基因-病毒的构建方法 |
US20070110719A1 (en) | 2003-11-14 | 2007-05-17 | Holm Per S | Novel use of adenoviruses and nucleic acids that code for said viruses |
US7473418B2 (en) | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
CN100361710C (zh) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用 |
US7714119B2 (en) * | 2004-07-13 | 2010-05-11 | Biosante Pharmaceuticals, Inc. | AAV vector compositions and methods for enhanced expression of immunoglobulins using the same |
US7943373B2 (en) * | 2004-09-29 | 2011-05-17 | Oncolys Biopharma, Inc. | Telomelysin/GFP-expressing recombinant virus |
US7632509B2 (en) * | 2005-07-19 | 2009-12-15 | Biosante Pharmaceuticals, Inc. | Methods to express recombinant proteins from lentiviral vectors |
WO2008108890A2 (fr) * | 2006-10-18 | 2008-09-12 | University Of Rochester | Réplication conditionnelle de virus pour thérapie cancéreuse |
US7621843B2 (en) * | 2007-01-17 | 2009-11-24 | General Electric Company | Apparatus for restraining axial movement of a ring gear in a gearbox for a wind turbine |
CN101617052A (zh) | 2007-01-30 | 2009-12-30 | 特兰斯吉恩股份有限公司 | 用于免疫的乳头瘤病毒e2多肽 |
CN101928696B (zh) * | 2008-09-27 | 2012-08-15 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 一种前列腺癌靶向腺病毒的制备及应用 |
ES2536747T3 (es) | 2009-01-20 | 2015-05-28 | Transgene Sa | ICAM 1 soluble como biomarcador para predicción de respuesta terapéutica |
NZ595290A (en) | 2009-03-24 | 2012-09-28 | Transgene Sa | Biomarker for monitoring patients |
RU2555340C2 (ru) | 2009-04-17 | 2015-07-10 | Трансжене Са | Биомаркер для мониторинга пациентов |
ES2385251B1 (es) | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
JP5650212B2 (ja) | 2009-07-10 | 2015-01-07 | トランジェーヌ、ソシエテ、アノニムTransgene S.A. | 患者を選択するためのバイオマーカーおよび関連方法 |
EP2655409A4 (fr) | 2010-12-22 | 2015-07-01 | Univ Leland Stanford Junior | Super-agonistes et antagonistes de l'interleukine-2 |
US9017672B2 (en) | 2012-05-11 | 2015-04-28 | Immunicum Aktiebolag | Hexon Tat-PTD modified adenovirus and uses thereof |
US9657076B2 (en) | 2012-10-23 | 2017-05-23 | Emory University | GM-CSF and IL-4 conjugates, compositions, and methods related thereto |
KR102089121B1 (ko) | 2013-03-14 | 2020-03-13 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양살상형 아데노바이러스 조성물 |
CN103463646A (zh) * | 2013-09-19 | 2013-12-25 | 浙江大学 | E2f1蛋白在制备诊断和治疗骨肉瘤药物中的应用 |
WO2015042707A1 (fr) | 2013-09-24 | 2015-04-02 | Medicenna Therapeutics Pte Ltd | Protéines hybrides de l'interleukine-2 et leurs utilisations |
WO2015164815A1 (fr) | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonistes, agonistes et antagonistes partiels de l'interleukine-2 |
EP3390428B1 (fr) | 2016-02-23 | 2019-09-25 | Salk Institute for Biological Studies | Dosage à haut débit pour mesurer la cinétique de réplication d'un adénovirus |
CN117384961A (zh) | 2016-02-23 | 2024-01-12 | 萨克生物研究学院 | 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达 |
CN110062630A (zh) | 2016-12-12 | 2019-07-26 | 萨克生物研究学院 | 肿瘤靶向合成腺病毒及其用途 |
JP7433051B2 (ja) | 2017-06-19 | 2024-02-19 | メディシナ セラピューティクス インコーポレイテッド | Il-2スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法 |
WO2022170219A1 (fr) | 2021-02-05 | 2022-08-11 | Iovance Biotherapeutics, Inc. | Traitement adjuvant du cancer |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994018992A1 (fr) * | 1993-02-16 | 1994-09-01 | Onyx Pharmaceuticals | Virus cytopathique pour le traitement et la prophylaxie de la neoplasie |
WO1998013508A1 (fr) * | 1996-09-24 | 1998-04-02 | Dana-Farber Cancer Institute | Methode de ciblage des cellules malignes au moyen d'un promoteur reagissant au facteur e2f |
US5885833A (en) * | 1996-02-13 | 1999-03-23 | Hoechst Aktiengesellschaft | Nucleic acid constructs for the cell cycle-regulated expression of genes and therapeutic methods utilizing such constructs |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5801029A (en) * | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
EP0707071B1 (fr) * | 1994-08-16 | 2003-07-30 | Crucell Holland B.V. | Vecteurs récombinants dérivés d'adénovirus pour la thérapie génique |
US5998205A (en) * | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
US20030026789A1 (en) * | 1995-05-03 | 2003-02-06 | Richard J. Gregory | Gene therapy using replication competent targeted adenoviral vectors |
US6197293B1 (en) * | 1997-03-03 | 2001-03-06 | Calydon, Inc. | Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof |
US6432700B1 (en) * | 1997-03-03 | 2002-08-13 | Cell Genesys, Inc. | Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same |
US6900049B2 (en) * | 1998-09-10 | 2005-05-31 | Cell Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
US7691370B2 (en) * | 1998-10-15 | 2010-04-06 | Canji, Inc. | Selectivity replicating viral vector |
GB9906815D0 (en) * | 1999-03-24 | 1999-05-19 | Isrec | Anti-neoplastic viral agents |
-
2000
- 2000-11-14 EP EP00978753A patent/EP1230378B1/fr not_active Expired - Lifetime
- 2000-11-14 DE DE60035124T patent/DE60035124T2/de not_active Expired - Lifetime
- 2000-11-14 DK DK00978753T patent/DK1230378T3/da active
- 2000-11-14 CA CA2380537A patent/CA2380537C/fr not_active Expired - Fee Related
- 2000-11-14 CN CN00813593A patent/CN1382218A/zh active Pending
- 2000-11-14 PT PT00978753T patent/PT1230378E/pt unknown
- 2000-11-14 AU AU16181/01A patent/AU776061B2/en not_active Ceased
- 2000-11-14 US US09/714,409 patent/US7001596B1/en not_active Expired - Fee Related
- 2000-11-14 JP JP2001538528A patent/JP4334174B2/ja not_active Expired - Fee Related
- 2000-11-14 ES ES00978753T patent/ES2288488T3/es not_active Expired - Lifetime
- 2000-11-14 AT AT00978753T patent/ATE364091T1/de active
- 2000-11-14 WO PCT/US2000/031590 patent/WO2001036650A2/fr active IP Right Grant
-
2007
- 2007-09-03 CY CY20071101140T patent/CY1107725T1/el unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994018992A1 (fr) * | 1993-02-16 | 1994-09-01 | Onyx Pharmaceuticals | Virus cytopathique pour le traitement et la prophylaxie de la neoplasie |
US5885833A (en) * | 1996-02-13 | 1999-03-23 | Hoechst Aktiengesellschaft | Nucleic acid constructs for the cell cycle-regulated expression of genes and therapeutic methods utilizing such constructs |
WO1998013508A1 (fr) * | 1996-09-24 | 1998-04-02 | Dana-Farber Cancer Institute | Methode de ciblage des cellules malignes au moyen d'un promoteur reagissant au facteur e2f |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7361354B1 (en) | 1999-11-25 | 2008-04-22 | Viralytics Limited | Methods for treating malignancies expressing ICAM-1 using coxsackie a group viruses |
US8722036B2 (en) | 1999-11-25 | 2014-05-13 | Viralytics Limited | Methods for treating malignancies using coxsackieviruses |
US7485292B2 (en) | 2002-12-18 | 2009-02-03 | Viralytics Limited | Method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
Also Published As
Publication number | Publication date |
---|---|
WO2001036650A2 (fr) | 2001-05-25 |
WO2001036650A3 (fr) | 2001-11-22 |
CA2380537A1 (fr) | 2001-05-25 |
EP1230378A2 (fr) | 2002-08-14 |
ATE364091T1 (de) | 2007-06-15 |
DE60035124T2 (de) | 2008-02-07 |
ES2288488T3 (es) | 2008-01-16 |
AU1618101A (en) | 2001-05-30 |
CY1107725T1 (el) | 2013-04-18 |
US7001596B1 (en) | 2006-02-21 |
CN1382218A (zh) | 2002-11-27 |
DE60035124D1 (en) | 2007-07-19 |
PT1230378E (pt) | 2007-09-17 |
EP1230378B1 (fr) | 2007-06-06 |
JP4334174B2 (ja) | 2009-09-30 |
JP2003535575A (ja) | 2003-12-02 |
CA2380537C (fr) | 2011-01-18 |
DK1230378T3 (da) | 2007-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU776061B2 (en) | An oncolytic adenovirus | |
US6110744A (en) | Diminishing viral gene expression by promoter replacement | |
NZ551443A (en) | Chimeric adenoviruses for use in cancer treatment | |
US7078030B2 (en) | Oncolytic adenovirus | |
EP1121441B1 (fr) | Vecteurs viraux a replication selective | |
US7396679B2 (en) | Oncolytic adenovirus | |
AU772963B2 (en) | Adenoviral vectors for treating disease | |
CA2351587A1 (fr) | Vecteurs viraux a expression tardive de transgenes | |
AU781775B2 (en) | Adenoviral vectors for treating disease | |
WO2000022136A2 (fr) | Vecteurs adenoviraux recombinants presentant des effacements dans la region e1a | |
MXPA01004989A (en) | Viral vectors with late transgene expression |